IL6-174 G/C gene polymorphism and its relation to serum IL6 in Egyptian children with community-acquired pneumonia

被引:27
作者
Zidan, Haidy E. [1 ]
Elbehedy, Rabab M. [2 ]
Azab, Seham F. [2 ]
机构
[1] Zagazig Univ, Fac Med, Dept Med Biochem, Zagazig, Egypt
[2] Zagazig Univ, Fac Med, Dept Pediat, Zagazig, Egypt
关键词
Interleukin-6; Genetic polymorphisms; Pediatrics; Community acquired pneumonia; PROMOTER POLYMORPHISM; INTERLEUKIN-6; GENE; SEPTIC SHOCK; STREPTOCOCCUS-PNEUMONIAE; ASSOCIATION; SEVERITY; SEPSIS; PREDICTION; GUIDELINES; MORTALITY;
D O I
10.1016/j.cyto.2014.02.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Cytokines are involved in the pathogenesis of community acquired pneumonia (CAP). The aim of this study is to investigate the association of IL6-174 G/C gene polymorphism with CAP in Egyptian children, to assess its effect on CAP outcome and to determine its effect on the serum IL6 levels in these children. IL6-174 G/C gene polymorphism was genotyped in 210 Egyptian children (100 patients with CAP and 110 healthy controls) using PCR-RFLP, while the serum IL6 levels were measured by ELISA method. We found a significant association between the GG genotype, G allele of IL6-174 G/C SNP and susceptibility to CAP (P= 0.02, 0.01 respectively). However, GG genotype and G allele were protective against severe sepsis (p = 0.004), acute respiratory failure (p <0.001) and hospital mortality (p < 0.001). Serum IL6 levels were significantly increased in these children while there was no relation between GG genotype and serum IL6. In conclusion, IL6-174 G/C gene polymorphism may contribute to susceptibility to CAP in Egyptian children. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:60 / 64
页数:5
相关论文
共 36 条
[1]
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[2]
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity [J].
Antunes, G ;
Evans, SA ;
Lordan, JL ;
Frew, AJ .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (04) :990-995
[3]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[4]
British Thoracic Society of Standards of Care Committee, 2011, THORAX, V57, pi1
[5]
The effect of the interleukin-6-174G &gt; C promoter gene polymorphism on endothelial function in healthy volunteers [J].
Brull, DJ ;
Lesson, CPM ;
Montgomery, HE ;
Mullen, M ;
deDivitiis, M ;
Humphries, SE .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 (03) :153-157
[6]
EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF RESPIRATORY-TRACT INFECTIONS [J].
CHOW, AW ;
HALL, CB ;
KLEIN, JO ;
KAMMER, RB ;
MEYER, RD ;
REMINGTON, JS .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S62-S88
[7]
Analysis of polymorphism at site-174 G/C of interleukin-6 promoter region in multiple myeloma [J].
Duch, C. R. ;
Figueiredo, M. S. ;
Ribas, C. ;
Almeida, M. S. S. ;
Colleoni, G. W. B. ;
Bordin, J. O. .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2007, 40 (02) :265-267
[8]
Systemic cytokine response in patients with community-acquired pneumonia [J].
Endeman, H. ;
Meijvis, S. C. A. ;
Rijkers, G. T. ;
van Velzen-Blad, H. ;
van Moorsel, C. H. M. ;
Grutters, J. C. ;
Biesma, D. H. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (06) :1431-1438
[9]
The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans [J].
Endler, G ;
Marsik, C ;
Joukhadar, C ;
Marculescu, R ;
Mayr, F ;
Mannhalter, C ;
Wagner, OF ;
Jilma, B .
CLINICAL CHEMISTRY, 2004, 50 (01) :195-200
[10]
Fischer CP, 2006, EXERC IMMUNOL REV, V12, P6